UNSPSC 51171720: Alosetron hydrochloride

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C17H18N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2F5R1A46YW, chemically known as 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1h-pyrido(4,3-b)indol-1-one monohydrochloride but more generally known as alosetron hydrochloride, which bears US NIH Compound Identifier 60758. The base compound, Alosetron, comes in base and hydrochloride forms.

UNSPSC 51171720 Alosetron hydrochloride is a Commodity code that maps to pharmaceutical procurement, but the recent state and local opportunities available show a substantial mismatch: the three posted solicitations involve drug testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements — none of which center on alosetron hydrochloride as a named product line. State and local governments purchasing under this code appear to be acquiring pharmaceuticals through wholesale and cooperative purchasing mechanisms rather than procuring a single active pharmaceutical ingredient. The issuing bodies span state health and human services agencies, county criminal-justice departments, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) is soliciting offender specimen collection and drug testing services via RFP 2026-327 with a response due July 23, 2026, at an estimated annual contract value of $600,000; the Texas Health and Human Services Commission issued an RFI on March 27, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products through March 26, 2026.

Geographic activity centers on Texas and Minnesota, with MMCAP's reach extending to participating state and local jurisdictions including Oregon. The Collin County RFP addresses approximately 25,031 annual tests using immunoassay screening with confirmation and oral fluid or hair testing alternatives, with contract performance at collection sites in Plano and McKinney from September 1, 2026 through five potential years. The MMCAP RFP seeks manufacturers to supply generic pharmaceuticals through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026 for a two-year term with optional extensions. The Texas HHS RFI signals early-stage market research for direct-to-manufacturer supply models outside traditional PBM and GPO channels, though no formal award timeline or funding allocation appears in the preliminary information-gathering phase.